DARPA Focused Pharma for Neuropsychiatric Symptoms

Sponsor Deadline: 

Nov 19, 2019

Letter of Intent Deadline: 

Oct 15, 2019

Sponsor: 

DOD Defense Advanced Research Projects Agency

UI Contact: 

DARPA Focused Pharma 
HR001119S0092
DARPA - Biological Technologies Office
Grants.gov  https://www.grants.gov/web/grants/view-opportunity.html?oppId=320660
FBO.gov  https://www.fbo.gov/index?s=opportunity&mode=form&id=def4a1a2bf25636f93b...

Abstract strongly encouraged by October 15, 2019, 4:00 PM ET.
Proposal deadline November 19, 2019, 4:00 PM ET.

Military service members and veterans face serious occupational trauma; one element in particular relates to the significantly increased risk of acute and chronic neuropsychiatric conditions. Neuropsychiatric conditions in the military are particularly impactful because options for treating them are limited. No therapy currently exists that can deliver rapid relief of neuropsychiatric symptoms and is reasonable for use in a broad spectrum of conditions. Neuropsychiatric conditions are complex, and presentation is highly subject to significant inter-individual variability. Focused Pharma aims to develop new drugs that target specific neurotransmitter receptor signaling modes to deliver near immediate relief that is generalizable across indications and individuals.

Categories: 

Keywords: